Chapel Hill, North Carolina Clinical Trials

A listing of Chapel Hill, North Carolina clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 64 clinical trials
A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal and genital) regions. This study will evaluate how well upadacitinib compared to placebo (no medicine) works to treat hidradenitis suppurativa (HS) in adult participants with moderate to severe disease. …

Duke University Medical Center /ID# 218526
 (8.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +27 other locations
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the …

antiandrogen therapy
orchiectomy
prednisone
metastasis
cancer
Research Site
 (8.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +106 other locations
Treatment of Moderate to Severe Lateral Canthal Lines

The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe LCL.

Aesthetic Solutions, PA
 (1.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +9 other locations
A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib

REMD-477 is a human anti-glucagon receptor antibody. Its proposed mechanism of action in controlling hyperglycemia is by blocking glucagon receptor (GCGR) signaling. In this way, it increases hepatic glucose uptake, decreases hepatic glycogenolysis and gluconeogenesis, increases glycogen synthesis, and ultimately decreases blood glucose levels. This protocol will test the hypotheses …

Duke University Medical Center
 (8.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19

The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate …

blood test
covid-19
University of North Carolina
 (3.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
A Study Evaluating JUV DERM VOLUMA XC Injectable Gel for Correction of Temple Hollowing in Adult Participants Over 22 Years Old

The objectives of this study are to evaluate the safety and effectiveness of Juvederm Voluma XC injectable gel in adult participants seeking correction of temple hollowing

Aesthetic Solutions, PA
 (1.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +14 other locations
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.

dulaglutide
body mass index
cardiovascular disease
tirzepatide
Duke University Medical Center
 (8.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +650 other locations
None

Duke University Medical Center
 (8.0 away) Contact site
  • 0 views
  • 19 May, 2025
  • +19 other locations
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.

aphasia
progranulin
pick's disease
dementia
University of North Carolina at Chapel Hill
 (1.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +46 other locations
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.

treatment regimen
lasmiditan
migraine
headache
ly573144
University of North Carolina School of Medicine - Children's Hospital - Children's Research Institute
 (1.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +162 other locations